Northern Trust Corp Impel Pharmaceuticals Inc Transaction History

Northern Trust Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.96 - $4.1 $131 - $561	-137 Reduced 1.03%	13,218 $18,000
Q3 2022 Nov 14, 2022	BUY	$5.78 - $9.32 $18,120 - $29,218	3,135 Added 30.68%	13,355 $65,000
Q2 2022 Aug 12, 2022	SELL	$5.83 - $10.12 $231,829 - $402,421	-39,765 Reduced 79.55%	10,220 $95,000
Q1 2022 May 13, 2022	BUY	$5.86 - $9.85 $3,885 - $6,530	663 Added 1.34%	49,985 $318,000
Q4 2021 Feb 08, 2022	SELL	$8.33 - $12.14 $10,095 - $14,713	-1,212 Reduced 2.4%	49,322 $426,000
Q3 2021 Nov 15, 2021	SELL	$8.38 - $26.13 $66,696 - $207,968	-7,959 Reduced 13.61%	50,534 $615,000
Q2 2021 Aug 13, 2021	BUY	$7.33 - $15.2 $428,753 - $889,093	58,493 New	58,493 $518,000

14.4K

Ticker IMPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 23,738,800
Market Cap $475K
Description
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The c...

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

Stay updated on Northern Trust Corp with notifications on news.